Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2596)
All Articles published online
|
Dec 7, 2006 (publication date) through Apr 18, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Medeiros-Filho JE, Mello IMVGC, Pinho JRR, Neumann AU, Malta FM, Silva LCD, Carrilho FJ. Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy. World J Gastroenterol 2006; 12(45): 7271-7277 [PMID: 17143940 DOI: 10.3748/wjg.v12.i45.7271] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v12/i45/7271.htm |
| Number | Citing Articles |
| 1 |
Harel Dahari, Jennifer E. Layden-Almer, Alan S. Perelson, Thomas J. Layden. Hepatitis C viral kinetics in special populations. Current Hepatitis Reports 2008; 7(3): 97 doi: 10.1007/s11901-008-0022-2
|
| 2 |
Wendy S.C. Cheng, Stuart K. Roberts, Geoffrey McCaughan, William Sievert, Martin Weltman, Darrell Crawford, William Rawlinson, Philippa S. Marks, James Thommes, Bishoy Rizkalla, Motoko Yoshihara, Gregory J Dore. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. Journal of Hepatology 2010; 53(4): 616 doi: 10.1016/j.jhep.2010.04.024
|
| 3 |
M. Lindh, B. Arnholm, A. Eilard, M. Färkkilä, K. Hellstrand, M. Lagging, N. Langeland, K. Mørch, S. Nilsson, C. Pedersen, M. R. Buhl, T. Wahlberg, R. Wejstål, J. Westin, G. Norkrans. Hepatitis C treatment response kinetics and impact of baseline predictors. Journal of Viral Hepatitis 2011; 18(6): 400 doi: 10.1111/j.1365-2893.2010.01323.x
|
| 4 |
T H T Nguyen, F Mentré, M Levi, J Yu, J Guedj. A Pharmacokinetic–Viral Kinetic Model Describes the Effect of Alisporivir as Monotherapy or in Combination With Peg-IFN on Hepatitis C Virologic Response. Clinical Pharmacology & Therapeutics 2014; 96(5): 599 doi: 10.1038/clpt.2014.173
|
| 5 |
Harel Dahari, Jennifer E. Layden–Almer, Eric Kallwitz, Ruy M. Ribeiro, Scott J. Cotler, Thomas J. Layden, Alan S. Perelson. A Mathematical Model of Hepatitis C Virus Dynamics in Patients With High Baseline Viral Loads or Advanced Liver Disease. Gastroenterology 2009; 136(4): 1402 doi: 10.1053/j.gastro.2008.12.060
|
| 6 |
Olav Dalgard, Kristian Bjøro, Helmer Ring-Larsen, Einar Bjornsson, Mona Holberg-Petersen, Eva Skovlund, Olle Reichard, Bjørn Myrvang, Bo Sundelöf, Ståle Ritland, Kjell Hellum, Aril Frydén, Jon Florholmen, Hans Verbaan. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2007; 47(1): 35 doi: 10.1002/hep.21975
|
| 7 |
E. S. A. Araújo, H. Dahari, A. U. Neumann, N. de Paula Cavalheiro, C. E. Melo, E. S. de Melo, T. J. Layden, S. J. Cotler, A. A. Barone. Very early prediction of response to HCV treatment with PEG‐IFN‐alfa‐2a and ribavirin in HIV/HCV‐coinfected patients. Journal of Viral Hepatitis 2011; 18(4) doi: 10.1111/j.1365-2893.2010.01358.x
|
| 8 |
Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim. Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. Clinical and Molecular Hepatology 2015; 21(4): 358 doi: 10.3350/cmh.2015.21.4.358
|
| 9 |
H. Guedj, J. Guedj, F. Negro, M. Lagging, J. Westin, P.‐Y. Bochud, S. Bibert, A. U. Neumann. The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1–infected patients treated with Peg‐IFN‐alfa‐2a and ribavirin. Journal of Viral Hepatitis 2012; 19(7): 488 doi: 10.1111/j.1365-2893.2011.01569.x
|
| 10 |
Lijuan Song, Cui Ma, Qiang Li, Aijun Fan, Kaifa Wang. Global dynamics of a viral infection model with full logistic terms and antivirus treatments. International Journal of Biomathematics 2017; 10(01): 1750012 doi: 10.1142/S1793524517500127
|
| 11 |
Jannick Verbeeck, Mark J. Stanley, Jen Shieh, Linda Celis, Els Huyck, Elke Wollants, Judy Morimoto, Alice Farrior, Erwin Sablon, Margaret Jankowski-Hennig, Carl Schaper, Pamela Johnson, Marc Van Ranst, Marianne Van Brussel. Evaluation of Versant Hepatitis C Virus Genotype Assay (LiPA) 2.0. Journal of Clinical Microbiology 2008; 46(6): 1901 doi: 10.1128/JCM.02390-07
|
| 12 |
Ijaz S Jamall, Shafaq Yusuf, Maimoona Azhar, Selene Jamall. Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?. World Journal of Gastroenterology 2008; 14(43): 6627-6631 doi: 10.3748/wjg.14.6627
|
| 13 |
P Colombatto, P Ciccorossi, AM Maina, L Civitano, F Oliveri, B Coco, V Romagnoli, F Bonino, MR Brunetto. Early and Accurate Prediction of Peg-IFNs/Ribavirin Therapy Outcome in the Individual Patient With Chronic Hepatitis C by Modeling the Dynamics of the Infected Cells. Clinical Pharmacology & Therapeutics 2008; 84(2): 212 doi: 10.1038/clpt.2008.21
|